Nanoparticle albumin-bound (nab-) paclitaxel is a solvent-free paclitaxel formulation that has been designed to reduce adverse reactions associated with conventional solvent-based paclitaxel formulations and to improve paclitaxel tumor penetration by exploiting the physiologic transport properties of albumin. In a recently reported phase 3 trial that compared nab-paclitaxel and solvent-based paclitaxel in combination with carboplatin as first-line treatment of advanced non–small-cell lung cancer (NSCLC), nab-paclitaxel was associated with a significantly greater overall response rate (ORR), the primary end point, and a reduced risk of neuropathy.1 The findings in this international trial, combined with the demonstration of paclitaxel efficacy in this setting, supported the recent approval of nab-paclitaxel combined with carboplatin as first-line treatment of advanced NSCLC. Subset analyses in the trial suggested some potential response and survival advantages with nab-paclitaxel treatment.

Of 1,052 patients with nonresectable stage 3B or stage 4 NSCLC, 521 received a weekly nab-paclitaxel 100 mg/m² infusion and 531 received conventional solvent-based paclitaxel 200 mg/m² every 3 weeks. All of the patients received carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks. Steroid/antihistamine premedication was required in the solvent-based paclitaxel group and was used at investigator discretion in the nab-paclitaxel group. Patients were to receive at least 6 cycles of treatment. The primary endpoint was ORR.

The median age of the patients was 60 years in the nab-paclitaxel and solvent-based paclitaxel groups, with 14% and 15% of patients, respectively, being 70 years or older; 75% of patients in both groups were men, and 80% and 82% were white. Global geographic distribution was balanced, with most patients being from Russia (46% and 44%) and Ukraine (23% and 25%), followed by Japan (14% and 14%) and the United States (12% and 11%). ECOG performance status was 1 in 74% of the nab-paclitaxel group, and 78% of the solvent-based paclitaxel group. Histology consisted of adenocarcinoma in 49% and 50% of patients, and squamous cell carcinoma in 44% and 42%; and 79% of each group had stage IV disease. In

What’s new, what’s important

The Food and Drug administration has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic non–small-cell lung cancer who are not candidates for surgery or radiation. The approval was based on results from the phase 3 CA031 trial, which showed that weekly nab-paclitaxel, a nanoparticle albumin-bound formulation of paclitaxel, combined with carboplatin significantly improved overall response rate (ORR), when compared with solvent-based paclitaxel plus carboplatin. All of the responses were partial, except for 1 complete response in the solvent-based paclitaxel group. ORR was significantly greater with nab-paclitaxel among patients with squamous cell histology (41% vs 24%, respectively; RRR, 1.680; P < .001), with no difference between treatments being observed in patients with nonsquamous histology (ORR, 26% vs 25%) or adenocarcinoma (ORR, 26% vs 27%).

Grade 3 and 4 thrombocytopenia and anemia were significantly more common in nab-paclitaxel patients than in solvent-based paclitaxel patients, but grade 3 and 4 neutropenia was significantly more common in solvent-based paclitaxel patients than in nab-paclitaxel patients, as were all grades of sensory neuropathy, grades 3 and 4 neuropathy, grade 3 myalgia and arthralgia. A subsequent analysis of a subset of patients 70 years or older reported that survival for the nab-paclitaxel arm was significantly longer in those patients (median OS, 19.9 vs 10.4 months), but it is not clear what that benefit is due to. Fewer side effects, better tolerability, and improved response rates are seen with nab-paclitaxel–containing regimen. That is a promising step forward and it could potentially help many patients. But lack of survival benefit is disappointing. In the era of molecular classification and targeting, this may not be the most exciting development in lung cancer treatment.

— Jame Abraham, MD
How I treat advanced NSCLC

Non–small-cell lung cancer frequently presents at an advanced stage. In this setting, chemotherapy has been shown not only to improve overall survival, but also quality of life. Platinum-based chemotherapy remains the mainstay of treatment for metastatic disease. Treatment of patients with advanced NSCLC usually begins with review of histology, which is an important factor for individualizing treatment. The use of bevacizumab and pemetrexed is restricted to patients with nonsquamous cell NSCLC. Superior treatment outcomes with pemetrexed in nonsquamous NSCLC and association of severe pulmonary hemorrhage with the use of bevacizumab in squamous NSCLC have led to these limitations. There are, as a consequence, fewer active agents for patients with squamous cell NSCLC compared with adenocarcinoma.

Nab-paclitaxel, which was recently approved for use as a first-line agent in the treatment of NSCLC showed higher response rate in squamous NSCLC, and improved overall survival in elderly patients, and represents an option for these subsets of patients. Advances in molecular characterization of NSCLC have made personalized approaches feasible. For patients with adenocarcinoma, especially never smokers and for those without significant smoking history, molecular testing is routinely used to guide therapeutic decisions. Detection of gain of function mutations in the epidermal growth factor receptor domain and ALK gene rearrangements select patients who benefit from the use of erlotinib and crizotinib respectively.

Maintenance therapy has also recently emerged as a treatment paradigm for advanced NSCLC. Continuation maintenance, where a part of initial chemotherapy is continued, and switch maintenance, where a new non–cross-resistant agent is introduced after completion of first-line therapy have been studied. As we gain a better understanding of the biology of NSCLC, patients should be offered enrollment and treatment as part of clinical trial. Several new treatments that irreversibly target EGFR, novel EML4-ALK inhibitors, and agents that target KRAS mutations are in development with encouraging early efficacy data.

— Charu Aggarwal, MD

Subgroup analyses suggested potential differences in survival according to geographic region and age. Median PFS was nonsignificantly prolonged with nab-paclitaxel treatment among the 165 patients from the US and Canada (7.0 vs 5.4 months; HR, 0.694) and among patients aged 70 years or older (8.0 vs 6.8 months; HR, 0.687). Median OS was significantly prolonged with nab-paclitaxel treatment in North American patients (12.7 vs 9.8 months; HR, 0.622; \( P < .005 \)) and in patients aged ≥ 70 years (19.9 vs 10.4 months; HR, 0.583; \( P = .009 \)). No differences between treatments were observed among 724 patients from Russia and Ukraine, among 149 patients from Japan, or among patients younger than 70 years. No significant differences in median OS were found between nab–paclitaxel and solvent-based paclitaxel patients with squamous histology (10.7 vs 9.5 months) or nonsquamous histology (13.1 vs 13.0 months).

Second-line therapy was used in 53% of the nab–paclitaxel group and in 54% of the solvent-based paclitaxel group. Use of second-line therapy was most common in Japan (85%), Australia (79%), and North America (69%) and least common in Russia and Ukraine (44%). As in the analysis in the overall population, the nab–paclitaxel group had a nonsignificant increase in OS among patients who received second-line therapy.
Safety data were reported as treatment-related adverse events. Grade 3 and 4 thrombocytopenia was significantly more common in nab-paclitaxel patients than in solvent-based paclitaxel patients (grade 3, 13% and 5% vs grade 4, 7% and 2%, respectively; \( P < .001 \)) as was anemia (grade 3, 22% and 5% vs grade 4, 6% and < 1%; \( P < .001 \)). Grade 3 and 4 neutropenia was significantly more common in solvent-based paclitaxel patients than in nab-paclitaxel patients (grade 3, 32% and 26% vs grade 4, 33% and 14%; \( P < .001 \)). Febrile neutropenia occurred in 1% of both groups. Sensory neuropathy of all grades was significantly more common with solvent-based paclitaxel (62% vs 46%; \( P < .001 \)), as was grade 3 and 4 neuropathy (11% and < 1% vs 3% and 0%; \( P < .001 \)). The median time to improvement of grade 3 or 4 sensory neuropathy to grade 1 was 38 days in the nab-paclitaxel group and 104 days in the solvent-based paclitaxel group. Grade 3 myalgia was more common with solvent-based paclitaxel (2% vs < 1%; \( P = .011 \)) as was grade 3 arthralgia (2% vs 0%; \( P = .008 \)). One treatment-related death occurred in each group.

Treatment was discontinued because of unacceptable toxicity without progressive disease in 12% of both groups, and because of adverse events in 4% of nab-paclitaxel patients and 5% of solvent-based paclitaxel patients. Paclitaxel dose reductions occurred in 46% of nab-paclitaxel patients and 23% of solvent-based paclitaxel patients, with reductions occurring primarily as a result of neutropenia (29% vs 10%), thrombocytopenia (13% vs 4%), anemia (6% vs < 1%), and sensory neuropathy (2% vs 6%). Overall, paclitaxel dose intensity was 26% greater and the cumulative paclitaxel dose was 18% greater in the nab-paclitaxel group. Dose delays occurred in 82% of nab-paclitaxel patients and in 54% of solvent-based paclitaxel patients.

Patients were assessed with the FACT-Taxane scale on day 1 of each treatment cycle. The nab-paclitaxel group exhibited a significantly greater improvement in mean change from baseline to final evaluation on this scale compared with the solvent-based paclitaxel group, including improvements on the neuropathy (\( P < .001 \)), pain (\( P < .001 \)), and hearing loss (\( P = .002 \)) subscales.

Reference